CHOEP + High Dose Therapy + Auto SCT for T-Cell Lymphoma
Status: Recruiting
Phase: Phase 2
Diagnosis: Hematopoietic Stem Cell Transplant
NCT ID: NCT01746173
(View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 12-388
This is a phase II study of CHOEP induction chemotherapy followed by autologous stem cell transplant using gemcitabine/busulfan/melphalan conditioning in patients with newly diagnosed systemic T-cell non-Hodgkin lymphoma.
Conducting Institutions:
Dana-Farber Cancer Institute, Brigham and Women's Hospital, Massachusetts General Hospital, Beth-Israel Deaconess Medical Center
Overall PI:
Philippe Armand, MD,
Dana-Farber Cancer Institute
Site-responsible Investigators:
Contacts:
Dana-Farber Cancer Institute:
Mildred Pasek,
mpasek@partners.org
Eligibility Criteria
Inclusion Criteria:
- Diagnosis of T-Cell lymphoma with mandatory pathologic review at Brigham and Women's
Hospital or Massachusetts General Hospital
- Measurable disease
- Candidate for Autologous Stem Cell Transplant
Exclusion Criteria:
- Prior anti-lymphoma chemotherapy (except steroids/radiotherapy for urgent palliation,
one prior cycle of CHOP or up to 2 prior cycles of CHOEP)
- Pregnant or breastfeeding
- Alk-positive ACL
- Significant neuropathy precluding vincristine administration
- Known hypersensitivity to any of the agents used in the treatment
- Uncontrolled intercurrent illness
- Receiving other investigational agents
- History of a different malignancy except if disease free for at least 5 years or have
cervical cancer in situ or basal cell/squamous cell carcinoma of the skin
- HIV positive on anti-retroviral therapy